Header Logo

Michael Horberg

Concepts (403)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
HIV Infections
127
2025
704
14.870
Why?
Anti-HIV Agents
39
2024
159
6.600
Why?
Antiretroviral Therapy, Highly Active
21
2020
94
3.370
Why?
Viral Load
29
2024
136
2.850
Why?
Humans
164
2025
17707
2.490
Why?
Anti-Retroviral Agents
21
2023
80
2.240
Why?
Male
118
2025
10094
2.130
Why?
Acquired Immunodeficiency Syndrome
12
2023
63
2.130
Why?
CD4 Lymphocyte Count
39
2024
181
2.050
Why?
Adult
104
2025
7658
2.030
Why?
Cohort Studies
65
2025
2589
1.960
Why?
Female
114
2025
12729
1.940
Why?
Middle Aged
94
2025
7976
1.910
Why?
Delivery of Health Care, Integrated
10
2021
531
1.860
Why?
Hepatitis C, Chronic
6
2021
64
1.490
Why?
Neoplasms
13
2025
442
1.420
Why?
Continuity of Patient Care
7
2022
103
1.410
Why?
United States
46
2024
3914
1.340
Why?
Hepatitis C
7
2022
64
1.260
Why?
Delivery of Health Care
7
2022
397
1.250
Why?
RNA, Viral
17
2024
65
1.230
Why?
Life Expectancy
4
2021
33
1.210
Why?
HIV-1
15
2017
73
1.210
Why?
Retrospective Studies
28
2024
2471
1.130
Why?
Patient Compliance
7
2015
299
1.130
Why?
Electronic Health Records
9
2024
694
1.110
Why?
Diabetes Mellitus
6
2024
483
1.100
Why?
Quality of Health Care
2
2020
276
1.020
Why?
Risk Factors
34
2024
3367
0.860
Why?
Reverse Transcriptase Inhibitors
5
2024
25
0.860
Why?
Health Services Accessibility
7
2020
280
0.860
Why?
Algorithms
3
2023
237
0.850
Why?
Healthcare Disparities
5
2017
203
0.780
Why?
Incidence
24
2024
1269
0.770
Why?
Ethnic Groups
5
2021
474
0.760
Why?
Treatment Outcome
13
2022
1254
0.750
Why?
Aged
37
2024
6150
0.740
Why?
Adolescent
26
2022
3671
0.740
Why?
Young Adult
25
2022
2450
0.730
Why?
Continental Population Groups
2
2015
301
0.710
Why?
Diabetic Foot
1
2020
3
0.710
Why?
Hepacivirus
5
2022
52
0.700
Why?
Raltegravir Potassium
2
2018
9
0.700
Why?
Anemia
3
2025
34
0.660
Why?
Quality Assurance, Health Care
2
2011
137
0.660
Why?
Patient Acceptance of Health Care
4
2020
387
0.660
Why?
California
23
2020
2327
0.640
Why?
District of Columbia
11
2024
17
0.640
Why?
Office Visits
3
2021
77
0.630
Why?
Canada
18
2023
66
0.620
Why?
Substance Abuse, Intravenous
3
2021
33
0.610
Why?
Disease Eradication
1
2018
3
0.600
Why?
Appointments and Schedules
2
2021
26
0.600
Why?
Comparative Effectiveness Research
2
2019
66
0.590
Why?
Product Surveillance, Postmarketing
1
2018
95
0.580
Why?
Sexual and Gender Minorities
3
2024
26
0.570
Why?
Coinfection
4
2023
30
0.570
Why?
Mass Screening
6
2020
667
0.560
Why?
Cardiovascular Diseases
5
2022
596
0.540
Why?
Medication Adherence
5
2020
245
0.520
Why?
Renal Insufficiency, Chronic
4
2024
181
0.520
Why?
Unnecessary Procedures
1
2016
23
0.510
Why?
Dyslipidemias
2
2024
62
0.510
Why?
Low Back Pain
1
2016
53
0.500
Why?
Diagnostic Imaging
1
2016
45
0.500
Why?
Syphilis
2
2020
17
0.500
Why?
Primary Health Care
8
2022
756
0.490
Why?
HIV
7
2023
26
0.480
Why?
Hypertension
4
2024
498
0.440
Why?
North America
12
2024
42
0.440
Why?
Viremia
2
2020
9
0.430
Why?
End Stage Liver Disease
3
2022
9
0.430
Why?
Cross-Sectional Studies
14
2024
1322
0.430
Why?
Prevalence
11
2024
882
0.420
Why?
HIV Seropositivity
2
2017
31
0.420
Why?
Insurance Coverage
4
2020
105
0.420
Why?
Health Services Research
1
2014
213
0.420
Why?
Organophosphorus Compounds
1
2013
3
0.420
Why?
Deoxycytidine
1
2013
7
0.410
Why?
Insurance, Health
2
2020
175
0.410
Why?
African Continental Ancestry Group
4
2017
162
0.400
Why?
Glomerular Filtration Rate
3
2023
154
0.400
Why?
Hepatitis B, Chronic
3
2022
27
0.400
Why?
Primary Prevention
1
2013
70
0.390
Why?
Socioeconomic Factors
5
2024
626
0.390
Why?
HIV Protease Inhibitors
5
2024
24
0.380
Why?
Drug Prescriptions
4
2023
151
0.380
Why?
Contraception
1
2011
25
0.370
Why?
Pregnancy in Diabetics
1
2011
21
0.370
Why?
Myocardial Infarction
3
2022
234
0.370
Why?
Hepatitis B
2
2023
42
0.370
Why?
Antiviral Agents
4
2022
94
0.360
Why?
Transgender Persons
2
2022
35
0.360
Why?
Diabetes Complications
1
2011
113
0.360
Why?
Sarcoma, Kaposi
3
2021
12
0.360
Why?
Health Services Administration
1
2010
3
0.350
Why?
Organophosphonates
1
2010
7
0.340
Why?
Fanconi Syndrome
1
2010
5
0.340
Why?
Adenine
1
2010
8
0.340
Why?
Proportional Hazards Models
10
2021
710
0.330
Why?
Tenofovir
4
2023
18
0.330
Why?
Substance-Related Disorders
5
2021
420
0.330
Why?
HIV Envelope Protein gp41
1
2009
4
0.330
Why?
Pyrrolidinones
1
2009
4
0.330
Why?
Peptide Fragments
1
2009
27
0.320
Why?
Databases, Factual
3
2023
311
0.320
Why?
Gemfibrozil
1
2009
5
0.320
Why?
Hypolipidemic Agents
1
2009
40
0.310
Why?
Oligopeptides
1
2008
6
0.310
Why?
Pyridines
1
2008
9
0.310
Why?
Alcohol Drinking
3
2021
361
0.310
Why?
Ritonavir
1
2008
14
0.310
Why?
Health Policy
5
2016
118
0.310
Why?
Comorbidity
8
2024
590
0.310
Why?
Diabetes Mellitus, Type 2
3
2022
755
0.300
Why?
Models, Theoretical
2
2019
68
0.300
Why?
Longitudinal Studies
6
2024
717
0.300
Why?
Mental Disorders
2
2022
276
0.300
Why?
Logistic Models
6
2014
918
0.290
Why?
Community Health Centers
3
2019
65
0.290
Why?
Aged, 80 and over
12
2019
1927
0.290
Why?
Depressive Disorder
2
2019
220
0.290
Why?
Serotonin Uptake Inhibitors
1
2008
71
0.290
Why?
Hospitalization
3
2022
805
0.280
Why?
Alcoholism
3
2021
332
0.280
Why?
Pharmacists
1
2007
50
0.270
Why?
Surgical Procedures, Operative
1
2006
16
0.270
Why?
Disease Progression
3
2023
266
0.260
Why?
Odds Ratio
5
2020
670
0.260
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
2
2022
172
0.250
Why?
Multivariate Analysis
5
2017
561
0.250
Why?
Drug Resistance, Multiple, Viral
3
2011
6
0.250
Why?
Anus Neoplasms
4
2020
26
0.250
Why?
Liver Neoplasms
3
2021
40
0.240
Why?
Follow-Up Studies
6
2017
1218
0.240
Why?
Age Distribution
5
2021
246
0.240
Why?
Sexually Transmitted Diseases
2
2022
54
0.230
Why?
Erythrocyte Indices
1
2024
2
0.230
Why?
Heart Failure
2
2022
398
0.230
Why?
Social Stigma
1
2024
16
0.230
Why?
Kidney Failure, Chronic
2
2017
151
0.230
Why?
Diagnostic Errors
1
2024
27
0.230
Why?
Research Design
4
2019
372
0.220
Why?
Medical Record Linkage
2
2015
37
0.220
Why?
Health Status Disparities
2
2019
147
0.220
Why?
Carcinoma, Hepatocellular
2
2021
26
0.220
Why?
Phenotype
1
2024
151
0.220
Why?
Weight Loss
3
2022
305
0.210
Why?
Age Factors
6
2020
918
0.210
Why?
Epidemics
2
2013
6
0.210
Why?
Fractures, Bone
1
2023
95
0.200
Why?
Treatment Failure
3
2012
35
0.200
Why?
Polymerase Chain Reaction
1
2022
49
0.200
Why?
Lymphoma, AIDS-Related
3
2011
18
0.200
Why?
Dementia
1
2024
112
0.200
Why?
Homosexuality, Male
3
2024
38
0.190
Why?
Herpes Zoster
2
2014
82
0.190
Why?
Life Tables
1
2021
9
0.190
Why?
Severity of Illness Index
2
2021
448
0.190
Why?
Medical Marijuana
1
2022
23
0.190
Why?
Mental Health
2
2022
161
0.190
Why?
Risk Assessment
6
2024
1106
0.190
Why?
Forecasting
1
2022
74
0.190
Why?
Mid-Atlantic Region
3
2021
9
0.190
Why?
Gastric Bypass
1
2022
71
0.190
Why?
Health Maintenance Organizations
3
2008
414
0.180
Why?
Health Care Surveys
1
2022
223
0.180
Why?
Obesity
2
2019
841
0.180
Why?
Hispanic Americans
3
2021
397
0.180
Why?
Infant, Newborn
2
2021
857
0.180
Why?
Guideline Adherence
2
2019
155
0.180
Why?
Outcome Assessment (Health Care)
2
2016
227
0.180
Why?
Time Factors
5
2016
1095
0.180
Why?
Weight Gain
2
2020
175
0.180
Why?
Amputation
1
2020
11
0.180
Why?
Temperature
1
2020
19
0.180
Why?
Obesity, Morbid
1
2022
120
0.180
Why?
Smoking
2
2021
483
0.180
Why?
Tobacco Smoking
1
2021
20
0.180
Why?
AIDS-Related Opportunistic Infections
3
2016
17
0.180
Why?
Benchmarking
1
2020
40
0.170
Why?
Managed Care Programs
2
2021
313
0.170
Why?
Self Report
1
2022
252
0.170
Why?
Bariatric Surgery
1
2022
128
0.170
Why?
Heterocyclic Compounds, 3-Ring
1
2020
2
0.170
Why?
HIV Integrase Inhibitors
1
2020
3
0.170
Why?
Unsafe Sex
1
2020
19
0.170
Why?
Practice Patterns, Physicians'
1
2023
324
0.170
Why?
Gonorrhea
1
2020
18
0.170
Why?
Chlamydia Infections
1
2020
22
0.170
Why?
Anticoagulants
1
2020
128
0.170
Why?
European Continental Ancestry Group
3
2020
523
0.170
Why?
Kidney Transplantation
2
2017
29
0.170
Why?
Lung Neoplasms
3
2021
260
0.170
Why?
Anti-Obesity Agents
1
2019
18
0.160
Why?
Health Plan Implementation
1
2019
36
0.160
Why?
Phentermine
1
2019
10
0.160
Why?
Appetite Depressants
1
2019
16
0.160
Why?
Creatinine
3
2023
65
0.160
Why?
Motivational Interviewing
1
2019
33
0.160
Why?
Drug Therapy, Combination
4
2021
115
0.160
Why?
Text Messaging
1
2019
29
0.160
Why?
Smoking Cessation
1
2020
193
0.150
Why?
Overweight
2
2019
270
0.150
Why?
Population Surveillance
3
2017
265
0.150
Why?
Body Mass Index
3
2019
970
0.150
Why?
Blood Glucose
1
2020
348
0.150
Why?
Disease Notification
1
1998
7
0.150
Why?
Opioid-Related Disorders
1
2021
165
0.150
Why?
United States Dept. of Health and Human Services
2
2014
7
0.150
Why?
Lymphoma, Non-Hodgkin
3
2015
24
0.150
Why?
Sex Distribution
2
2015
189
0.150
Why?
Referral and Consultation
2
2019
165
0.140
Why?
CD4-Positive T-Lymphocytes
1
2017
14
0.140
Why?
Telemedicine
1
2021
185
0.140
Why?
Living Donors
1
2017
3
0.140
Why?
Graft Rejection
1
2017
5
0.140
Why?
Common Variable Immunodeficiency
1
2017
5
0.140
Why?
Critical Pathways
1
2017
11
0.140
Why?
Gastroenterology
1
2017
19
0.140
Why?
Societies, Medical
1
2017
74
0.140
Why?
Pneumonia
1
2017
51
0.130
Why?
Pneumococcal Infections
1
2016
42
0.130
Why?
HIV Protease
2
2006
4
0.130
Why?
Immunocompromised Host
2
2014
18
0.130
Why?
Dideoxynucleosides
1
2016
8
0.130
Why?
African Americans
4
2021
465
0.130
Why?
Glycated Hemoglobin A
3
2022
215
0.130
Why?
Pneumococcal Vaccines
1
2016
66
0.130
Why?
Regression Analysis
3
2013
296
0.130
Why?
Geography
1
2016
39
0.130
Why?
Patient Care
1
2016
35
0.130
Why?
Prognosis
4
2025
613
0.120
Why?
Diffusion of Innovation
1
2015
37
0.120
Why?
Sex Factors
4
2020
639
0.120
Why?
Prospective Studies
3
2022
1287
0.120
Why?
Kidney Function Tests
2
2017
22
0.120
Why?
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
1
2014
5
0.120
Why?
Risk
4
2021
517
0.120
Why?
Safety-net Providers
1
2015
51
0.110
Why?
Neuralgia
1
2014
3
0.110
Why?
Quality Indicators, Health Care
1
2015
142
0.110
Why?
Prostate-Specific Antigen
1
2014
75
0.110
Why?
Hepatitis C Antibodies
1
2014
3
0.110
Why?
Internet
2
2013
229
0.110
Why?
Healthcare Financing
1
2013
4
0.110
Why?
Government Programs
1
2013
11
0.110
Why?
Breast Neoplasms
1
2021
956
0.110
Why?
Methicillin-Resistant Staphylococcus aureus
1
2013
6
0.100
Why?
Staphylococcal Infections
1
2013
14
0.100
Why?
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
1
2013
3
0.100
Why?
Protease Inhibitors
1
2012
6
0.100
Why?
Drug Combinations
1
2013
43
0.100
Why?
Survival Rate
1
2013
262
0.100
Why?
Herpesvirus 3, Human
1
2012
44
0.100
Why?
Liver Diseases
1
2012
23
0.100
Why?
Drug Resistance, Viral
2
2009
12
0.100
Why?
Survival Analysis
4
2016
216
0.100
Why?
Biomarkers
1
2013
312
0.100
Why?
Prostatic Neoplasms
1
2014
262
0.100
Why?
Aging
3
2022
163
0.100
Why?
Case-Control Studies
4
2017
1117
0.090
Why?
Bayes Theorem
2
2022
72
0.090
Why?
Stroke
1
2014
316
0.090
Why?
Tuberculosis
1
2011
23
0.090
Why?
Urination Disorders
1
2011
10
0.090
Why?
Erectile Dysfunction
1
2011
24
0.090
Why?
Pandemics
2
2023
286
0.090
Why?
Cooperative Behavior
3
2016
89
0.090
Why?
Delayed Diagnosis
1
2010
19
0.090
Why?
Confidentiality
2
2022
25
0.080
Why?
Confounding Factors (Epidemiology)
2
2009
86
0.080
Why?
Likelihood Functions
1
2010
45
0.080
Why?
Appendicitis
1
2009
15
0.080
Why?
Hemoglobins
2
2024
39
0.080
Why?
Mutation
2
2011
131
0.080
Why?
Colorectal Neoplasms
2
2015
616
0.080
Why?
Atazanavir Sulfate
1
2008
5
0.080
Why?
Pregnancy Complications
1
2011
203
0.080
Why?
Triglycerides
1
2009
89
0.080
Why?
Sustained Virologic Response
2
2019
17
0.080
Why?
Mortality
1
2009
118
0.080
Why?
Interrupted Time Series Analysis
2
2021
25
0.080
Why?
Pregnancy
2
2011
1535
0.080
Why?
History, 21st Century
2
2019
24
0.080
Why?
Cholesterol, LDL
1
2009
119
0.080
Why?
Predictive Value of Tests
3
2017
355
0.070
Why?
Health Promotion
1
2011
280
0.070
Why?
AIDS Serodiagnosis
1
2007
10
0.070
Why?
Recurrence
2
2022
189
0.070
Why?
Program Evaluation
2
2020
222
0.070
Why?
Medical Indigency
1
2006
4
0.070
Why?
Quality Improvement
2
2020
189
0.060
Why?
Early Detection of Cancer
3
2021
513
0.060
Why?
Drug Information Services
1
2005
3
0.060
Why?
Medication Errors
1
2005
7
0.060
Why?
Drug Utilization Review
1
2005
24
0.060
Why?
Registries
3
2013
470
0.060
Why?
Infant
2
2022
1199
0.060
Why?
Drug Administration Schedule
3
2013
100
0.060
Why?
Medical Records Systems, Computerized
1
2005
83
0.060
Why?
Evidence-Based Practice
2
2015
46
0.060
Why?
Genotype
3
2011
227
0.060
Why?
Multimorbidity
1
2024
14
0.060
Why?
Kaplan-Meier Estimate
2
2015
129
0.050
Why?
DNA, Viral
1
2023
17
0.050
Why?
Hepatitis B virus
1
2023
20
0.050
Why?
Eligibility Determination
1
2022
12
0.050
Why?
Patient Participation
2
2015
132
0.050
Why?
RNA
1
2022
12
0.050
Why?
Kidney
1
2023
53
0.050
Why?
Gastrectomy
1
2022
46
0.050
Why?
Gender Identity
1
2022
33
0.050
Why?
Anxiety Disorders
1
2022
90
0.050
Why?
Documentation
1
2022
42
0.050
Why?
Prescriptions
1
2022
28
0.050
Why?
Sexual Behavior
1
2022
123
0.050
Why?
Administration, Oral
1
2020
84
0.040
Why?
Oxazines
1
2020
2
0.040
Why?
Condoms
1
2020
33
0.040
Why?
Piperazines
1
2020
9
0.040
Why?
Pyridones
1
2020
8
0.040
Why?
Patient Protection and Affordable Care Act
1
2020
42
0.040
Why?
Immunosuppression
1
2020
7
0.040
Why?
Sexual Partners
1
2020
38
0.040
Why?
Pilot Projects
1
2021
215
0.040
Why?
Epidemiologic Methods
2
2010
80
0.040
Why?
Mood Disorders
1
2019
18
0.040
Why?
Esophageal and Gastric Varices
1
2019
4
0.040
Why?
Washington
1
2020
382
0.040
Why?
Liver
1
2019
33
0.040
Why?
Clinical Trials as Topic
1
2020
131
0.040
Why?
Gastrointestinal Hemorrhage
1
2019
20
0.040
Why?
Liver Cirrhosis
1
2019
35
0.040
Why?
Insulin
1
2020
213
0.040
Why?
Blood Pressure
1
2021
300
0.040
Why?
Minority Groups
1
2019
101
0.040
Why?
Prediabetic State
1
2019
56
0.040
Why?
Reproducibility of Results
1
2019
371
0.040
Why?
Cost-Benefit Analysis
1
2019
243
0.040
Why?
Depressive Disorder, Major
1
2019
123
0.040
Why?
Molecular Sequence Data
2
2009
18
0.040
Why?
Communication
1
2020
191
0.040
Why?
Anxiety
1
2019
152
0.040
Why?
Behavior Therapy
1
2019
144
0.040
Why?
Prejudice
1
1998
23
0.040
Why?
Hypoglycemic Agents
1
2020
271
0.040
Why?
Graft Survival
1
2017
3
0.040
Why?
Nephrectomy
1
2017
6
0.040
Why?
Chronic Disease
1
2020
416
0.030
Why?
Child
2
2015
2481
0.030
Why?
Patient Outcome Assessment
1
2017
28
0.030
Why?
Serogroup
1
2016
10
0.030
Why?
Streptococcus pneumoniae
1
2016
19
0.030
Why?
Surveys and Questionnaires
2
2011
1322
0.030
Why?
Decision Support Techniques
1
2017
88
0.030
Why?
United States Department of Veterans Affairs
1
2017
120
0.030
Why?
Vaccines, Conjugate
1
2016
59
0.030
Why?
Patient Care Team
1
2017
111
0.030
Why?
Health Surveys
1
2017
260
0.030
Why?
Risk Reduction Behavior
1
2016
108
0.030
Why?
Inservice Training
1
2015
13
0.030
Why?
Demography
1
2016
100
0.030
Why?
Nutrition Surveys
1
2015
61
0.030
Why?
Confidence Intervals
1
2016
237
0.030
Why?
Reminder Systems
1
2015
80
0.030
Why?
Depression
1
2019
504
0.030
Why?
Practice Guidelines as Topic
1
2015
314
0.030
Why?
Post-Exposure Prophylaxis
1
2013
1
0.030
Why?
Platelet Count
1
2013
9
0.030
Why?
Clinical Protocols
1
2013
42
0.030
Why?
Aspartate Aminotransferases
1
2013
13
0.030
Why?
Alanine Transaminase
1
2013
22
0.030
Why?
Hematologic Neoplasms
1
2012
7
0.030
Why?
Reference Values
1
2012
93
0.030
Why?
SEER Program
1
2012
92
0.030
Why?
Virus Replication
1
2011
13
0.020
Why?
Vaccination
1
2016
656
0.020
Why?
Attitude of Health Personnel
1
2013
211
0.020
Why?
Phosphodiesterase 5 Inhibitors
1
2011
4
0.020
Why?
HIV Seronegativity
1
2011
12
0.020
Why?
Statistics, Nonparametric
1
2011
49
0.020
Why?
Clinical Laboratory Techniques
1
2011
10
0.020
Why?
Child, Preschool
1
2015
1417
0.020
Why?
Psychometrics
1
2011
122
0.020
Why?
Immunization Programs
1
2011
65
0.020
Why?
Data Interpretation, Statistical
1
2009
75
0.020
Why?
Carcinoma, Squamous Cell
1
2009
55
0.020
Why?
Models, Statistical
1
2009
177
0.020
Why?
Financing, Government
1
2007
27
0.020
Why?
Influenza Vaccines
1
2011
275
0.020
Why?
Quality of Life
1
2011
521
0.020
Why?
Evolution, Molecular
1
2006
2
0.020
Why?
Base Sequence
1
2006
19
0.020
Why?
Nelfinavir
1
2006
4
0.020
Why?
Phylogeny
1
2006
14
0.020
Why?
Research
1
2007
64
0.020
Why?
Medicare
1
2007
199
0.020
Why?
Medicaid
1
2007
188
0.020
Why?
Pregnancy Complications, Infectious
1
2007
147
0.020
Why?
Drug Interactions
1
2005
20
0.020
Why?
Polymorphism, Genetic
1
2005
63
0.020
Why?
Patient Education as Topic
1
2005
212
0.010
Why?
Concepts (403)
Explore
_
Co-Authors (56)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
-->

© 2025 Kaiser Permanente